TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06481657

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: train with oxygen and without oxygen enrichment (placebo).
Description: The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: train with oxygen and without oxygen enrichment (placebo).
Description: The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).
Study: NCT05137886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.
Study: NCT05929885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose OXIRI (LD-OXIRI)
Description: The LD-OXIRI regimen will be administered in the following sequence:~* metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~* intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~* intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1\*6 and UGT1A1\*28 genotype status.
Study: NCT05853185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBRRM®
Description: Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
Study: NCT05510609

Intervention type: DEVICE
Group type: OTHER
Intervention: BK 5000 Ultrasound Machine
Description: Both 2D and 3D ultrasound is being used. 3D using optical tracking.
Study: NCT04469803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intra-Shift Napping
Description: The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intra-Shift Napping
Description: The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intra-Shift Napping
Description: The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intra-Shift Napping
Description: The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intra-Shift Napping
Description: The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intra-Shift Napping
Description: The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.
Study: NCT04720378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: 1X ST266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: 1X ST266
Study: NCT05450952

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theanine Formulation
Description: Theanine Formulation Tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet
Study: NCT06057636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Hypnosis
Description: Participants will choose from one of three 20-minute prerecorded hypnosis audio files. Practices using the recordings will be documented on the hypnosis practice log.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered White Noise Hypnosis
Description: Participants will be listening to the same 20-minute white noise audio recording for 6 weeks and will be encouraged to practice daily. Practices using the recordings will be documented on the hypnosis practice log.
Study: NCT04720378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: 1X ST266
Study: NCT06183632

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: 3 x 7mL EDTA blood tubes
Study: NCT02785224

Intervention type: DRUG
Intervention: Vasopressin Steroids Epinephrine
Description: Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
Study: NCT05533398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress ball use
Description: They were asked to use the ball for at least 10 minutes during the dialysis treatment and when they felt stressed or unwell at home/work. Patients with arteriovenous fistula or arteriovenous graft were instructed to use the stress ball with the other hand, where there was no vascular access.
Study: NCT06526455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: oral drug 3-56 days after ESD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: oral drug 3-56 days after ESD.
Study: NCT06051825

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels
Description: Blood analysis of CRP and WBC levels Saliva analysis of CRP levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels
Description: Blood analysis of CRP and WBC levels Saliva analysis of CRP levels
Study: NCT05094895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stretta
Description: Radiofrequency energy delivered to the gastro-esophageal junction

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
Study: NCT05905757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dexmedetomidin + bupivacaine
Description: dexmedetomidine was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol + Bupivacaine
Description: tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
Study: NCT04794946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covishield
Description: 2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Covishield
Description: 2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
Study: NCT05927272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SKIN SAMPLES
Description: At baseline: one 4 mm Ø skin biopsies: on forearms (excluding skin folds): fresh At month 3 and month 6: Two 4 mm Ø skin biopsies will be performed on the same lesion selected at baseline (one on a repigmented area, one on a non-responded area): fresh~Fresh Skin biopsies will be analyzed the same day using Single-cell RNA sequencing (scRNAseq).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.
Study: NCT04980898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WoundEL medical device
Description: The WoundEl system is composed by: a class IIa device , a class IIb dressing electrode and a class I disperser electrode.~Applied to the leg ulcer, WoundEL® reproduces the endogenous electrical current to stimulate all the factors contributing to healing. Electrical current is evenly spread over the Dressing Electrode which also maintains a moist wound healing environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard cares
Description: Cleaning and monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard cares
Description: Cleaning and monitoring
Study: NCT05974046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]IDV184001AN
Description: \[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension
Study: NCT05927272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narrowband UVB
Description: narrowband UVB (Nb-UVB) 2 times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Steroids
Description: Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
Study: NCT05340322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colposcopy using pocket colpscope and thermocoagulator
Description: If HPV+, visualization with pocket colposcope and treatment with thermocoagulator
Study: NCT05779605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based training
Description: Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Center-based training
Description: Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
Study: NCT05897112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A received cryotherpay
Description: Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B received 10% Potassium Hydroxide Solution
Description: Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
Study: NCT05723679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HeO2 gas mixture
Description: Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HeO2 gas mixture
Description: Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room air gas mixture
Description: Normal room air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room air gas mixture
Description: Normal room air
Study: NCT04884867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based supportive skills delivered by phone by lay coaches
Description: 8-10 weekly coaching sessions delivered by telephone
Study: NCT06428318

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Sputum culture
Description: Sputum culture was done to patients and they received Antibiotics According to its results

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BioFire Pneumonia Panel (BFPP)
Description: BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
Study: NCT05526326

Intervention type: DEVICE
Intervention: Transplant with normothermic machine perfused (NMP) donor liver
Description: The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®
Study: NCT04744350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of FFP type IIb and IIc
Description: Patients will either be randomized in the surgical or conservative group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of FFP type IIb and IIc
Description: Patients will either be randomized in the surgical or conservative group.
Study: NCT06157762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: ultrasound guided lumbar erector spinae plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block performed by surgeon
Description: Erector spinae plane block performed by surgeon
Study: NCT04948580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Teachers (ICC-T)
Description: Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
Study: NCT05191303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile intervention of breastfeeding counseling
Description: The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
Study: NCT05037669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PACE CART19
Description: PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PACE CART19
Description: PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
Study: NCT05172037

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novaferon
Description: a novel recombinant antiviral protein drug

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT04991493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride
Description: pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia.
Study: NCT02329093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: To MRI-detecting bone signal changes in radiographic hip OA
Description: To examine whether or not non-weight bearing reduced OA progression
Study: NCT06017882

Intervention type: OTHER
Intervention: Partial sleep deprivation

Intervention type: OTHER
Intervention: Partial sleep deprivation

Intervention type: OTHER
Intervention: Partial sleep deprivation

Intervention type: OTHER
Intervention: Partial sleep deprivation
Study: NCT05188638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Inhaled Solution (SIS)
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Inhaled Solution (SIS)
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Inhaled Solution (SIS)
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Inhaled Solution (SIS)
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Inhaled Solution (SIS)
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Inhaled Solution (SIS)
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Inhaled Solution (SIS)
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile isotonic saline
Study: NCT04877327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Cryotherapy and radiofrequency
Study: NCT05501639

Intervention type: DRUG
Intervention: tiotropium
Description: tiotropium

Intervention type: DRUG
Intervention: long-acting β2-agonists (LABA)
Description: long-acting β2-agonists (LABA)

Intervention type: DRUG
Intervention: inhaled corticosteroids (ICS)
Description: inhaled corticosteroids (ICS)

Intervention type: DRUG
Intervention: inhaled corticosteroids (ICS)
Description: inhaled corticosteroids (ICS)
Study: NCT05268705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-day diet
Description: The participants must follow a 7-day high-carbohydrate-low-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-day diet
Description: The participants must follow a low-carbohydrate-high-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-day diet
Description: The participants must follow a low-carbohydrate-low-fat-high-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.